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A genome-wide association study of Han Chinese subjects was conducted to identify genetic susceptibility loci for nonobstructive azoo-
spermia (NOA). In the discovery stage, 802 azoospermia cases and 1,863 controls were screened for genetic variants in the genome.
Promising SNPs were subsequently confirmed in two independent sets of subjects: 818 azoospermia cases and 1,755 controls from
northern China, and 606 azoospermia cases and 958 controls from central and southern China. We detected variants at human leuko-
cyte antigen (HLA) regions that were independently associated with NOA (HLA-DRA, rs3129878, pcombine ¼ 3.70 3 1016, odds ratio
[OR]¼ 1.37; C6orf10 and BTNL2, rs498422, pcombine¼ 2.433 1012, OR¼ 1.42). These findings provide additional insight into the path-
ogenesis of NOA.Azoospermia (MIM 415000), defined as the absence of
spermatozoa in the ejaculate, affects 1% of the general
population and 10%–15% of infertile men.1,2 Compared
with obstructive azoospermia, which can be treated by
testicular sperm extraction and intracytoplasmic sperm
injection, nonobstructive azoospermia (NOA) is more
common, accounting for 60% of azoospermia, and more
difficult to treat because of spermatogenesis failure.2,3
Several genetic abnormalities have been associated with
NOA, including Y chromosome microdeletions and chro-
mosomal abnormalities.4,5 However, these known genetic
alterations account for a small portion of NOA cases,
whereas most cases are idiopathic.6 Sequence variants in
dozens of spermatogenesis genes have been evaluated for
the identification of additional NOA risk-associated genetic
alterations through the use of a candidate-gene approach.7
A genome-wide association study (GWAS) was also per-
formed among 40 NOA cases and 80 controls of European
descent.8 However, none of the sequence variants reached
a genome-wide significance level, nor were they consis-
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variants associated with idiopathic NOA.
Thus, to identify genetic susceptibility loci for NOA, we
conducted a three-stage GWAS with the goal of identifying
SNPs in the genome that are associated with risk for NOA
in the Han Chinese population.
Written informed consentwas obtained fromall subjects.
Additional demographic information was collected from
both cases and controls througha structuredquestionnaire.
This study was approved by each participating center’s
institutional ethics committee and was conducted accord-
ing to Declaration of Helsinki principles. Cases included
in this study were selected on the basis of an andrological
examination that included medical history, physical
examination, semen analysis, hormone analysis, scrotal
ultrasound, karyotype testing, andYchromosomemicrode-
letion screening. Cases with varicocele, cryptorchidism
(MIM 219050), obstructive azoospermia, hypogonado-
tropic hypogonadism (MIM 146110), recurrent infections,
testis trauma, iatrogenic infertility, karyotype anomalies,
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In stage I, genetic variants in the genome were screened
among 802 NOA cases and 1,863 controls. None of the
NOA cases had detectable sperm in the ejaculate after eval-
uation of the centrifuged pellet, nor did they have any
other known etiology. The NOA cases were all recruited
from Shandong province in northern China. Population
controls included 1,000 men from a community-based
study in Shanghai and 863 healthy women from the Shan-
dong province.
Subjects in stage II included 818 NOA cases and 1,755
controls born in eight provinces of northern China12
(Shandong, Heilongjiang, Jilin, Liaoning, Hebei, Henan,
Tianjin, and Beijing). Subjects in stage III included 606
NOA cases and 958 controls, all born in five provinces of
central and southern China (Jiangsu, Anhui, Shanghai,
Hubei, and Guangxi). Inclusion criteria for controls were
sperm concentration > 20 million/ml, progressive sperm
motility > 40%, viability > 50% on the basis of a
membrane structure test, normal sperm heads > 30%,
and normal sperm tails > 65%, in accordance with World
Health Organization criteria (1999).13
EDTA anticoagulated venous blood samples were
collected from all participants. Genomic DNA was ex-
tracted from peripheral-blood lymphocytes by standard
procedures with the use of FlexiGene DNA kits (QIAGEN)
and diluted to working concentrations of 50 ng/ml for
genome-wide genotyping and 15–20 ng/ml for the valida-
tion study.
Two genotyping methods were used for GWAS in stage I.
For NOA cases and population controls from the Shanghai
region, the HumanOmniExpress (OmniExpress) BeadChip
was used (Illumina, San Diego, CA, USA). For population
controls from the Shandong region, the Affymetrix
Genome-Wide Human SNPArray 6.0 was used (Affymetrix,
Santa Clara, CA, USA).
A series of quality control steps were applied so that
high-quality samples and SNPs were obtained. Subjects
were excluded from the analysis if the genotype call rate
was less than 95%. SNPs were excluded if (1) the missing
rate was > 2% in any of the three sets of subjects, (2)
the p value for Hardy-Weinberg equilibrium (HWE)
was < 0.001 in any of the two control subsets, or (3) minor
allele frequency was < 0.03 in the entire cohort. A total of
912,924 SNPs were retained in the analysis.
Two criteria were used to select SNPs from stage I for
further confirmation in stage II: (1) SNPs that were associ-
ated with NOA risk at p< 106 and (2) the most significant
SNP from each independent associated region as defined
by the CLUMP computer program (with an r2 of 0.5 as
a cutoff for linkage disequilibrium [LD] among SNPs). A
total of 37 SNPs were selected for confirmation in stage
II. Genotyping of five SNPs failed due to poor clusters.
Four SNPs that were confirmed in stage II at p < 0.001
(adjusted for 32 tests) were selected for further confirma-
tion in stage III.
Genotyping of SNPs in the confirmation stages
(II and III) was performed with the Sequenom iPLEXThe Amplatform (Sequenom, San Diego, CA, USA). PCR and ex-
tension primers for the SNPs were designed with the
MassARRAYAssay Design 3.0 software. PCR and extension
reactions were performed according to the manufacturer’s
instructions, and extension product sizes were determined
by mass spectrometry via the Sequenom iPLEX system. All
genotyping reactions were performed in 384-well plates.
Each plate included a duplicate for three or four subjects
selected at random, as well as six to nine negative controls
in which water was substituted for DNA. The average
concordance rate was 99.8%.
Tests for HWE were performed for each SNP separately
among case patients and control subjects with the use of
Fisher’s exact test. The EIGENSTRAT computer program
was used to examine the potential effect of population
substructure and to obtain principal components (eigens)
based on genotyped data.14 The IMPUTE computer
program was used for inferring the genotypes of SNPs
(e.g., SNPs catalogued in Hapmap phase II CHB [Han
Chinese in Beijing] population release no. 24) in the
genome that were not directly genotyped.15 A posterior
probability of >0.90 was applied to call genotypes that
were imputed from IMPUTE software. Allele frequency
differences between case patients and control subjects
were tested for each genotyped and imputed SNP, adjusted
for age and the first two eigen vectors, as implemented in
PLINK.16 Regional plots were generated with the computer
program LocusZoom.17 We used the Haploview software
(version 4.1) to infer the LD structure in the vicinity of
the susceptibility loci.18
In stage I, genotype frequencies of SNPs in the genome
were compared between 802 NOA cases and 1,863 control
subjects. An allelic test adjusted for age and the first
principal component (eigen) of a population stratification
analysis (Figure 1) showed that multiple SNPs in the
genome were significantly associated with NOA risk, at
p < 9.99 3 105 (Figure 2). Considering that some of these
SNPs were in LD, we performed a CLUMP analysis to iden-
tify independent associations, using an r2 of 0.5 as a cutoff
for LD among SNPs. This analysis revealed 37 regions
in the genome that were associated with NOA risk
(Table S1 available online). We then selected the most sig-
nificant SNP in each of these 37 regions for confirmation in
an additional 818 NOA cases and 1,755 controls from
northern China (stage II). Among 32 successfully geno-
typed SNPs, four (rs498422, rs2076531, rs3129878, and
rs7192, all at 6p22) were confirmed to be associated with
NOA risk, at p < 0.001. This p value cutoff was chosen to
guard against inflated type I error due to 32 tests (%5%
type I error). As a further confirmation, we compared the
allele frequencies of these four SNPs in an additional 606
NOA cases and 958 subjects without NOA from central
and southern China (stage III). The NOA risk-associated
alleles of these SNPs were consistently higher in NOA cases
than in controls in this stage; however, the evidence of
association for those four SNPs was marginally significant
(p ranged from 0.02 to 0.07, Table 1). Finally, to assesserican Journal of Human Genetics 90, 900–906, May 4, 2012 901
Figure 1. Quantile-Quantile Plots
The quantile-quantile plot of observed versus expected test statis-
tics was adjusted for age and first eigen (c2 test).the overall evidence for association between the SNPs and
NOA risk, we performed a combined allelic test for the
three stages based on a logistic regression analysis, adjusted
for age and stage information. The combined p value
ranged from 2.43 3 1012 to 3.70 3 1016 for these four
SNPs (Table 1), each exceeding a genome-wide significance
level of 5 3 108.
Considering that these four SNPs all reside in a 144 kb
genomic region at 6p22, we tested for independent associ-
ation of these SNPs with NOA risk among subjects in stage
I by using a stepwise multivariate analysis. Two SNPs
(rs3129878 and rs498422) were retained in the model,
and each showed a highly significant association with
NOA risk, with p value of 1.55 3 1011 and 4.19 3 108,
respectively.
This result suggests that these two SNPs were indepen-
dently associated with NOA risk, whereas the observed902 The American Journal of Human Genetics 90, 900–906, May 4, 2associations of two other SNPs (rs2076531 and rs7192)
with NOA risk in the univariate analysis were probably
partly due to their LD with these two SNPs. Similar results
were found in subjects from stages II and III, and two SNPs
(rs3129878 and rs498422) were retained in the multivar-
iate analysis (p ¼ 0.0002 and p ¼ 0.0008, respectively).
An examination of LD structure (based on the CHB
and JPT [Japanese in Tokyo] HapMap populations) and
known genes at the 6p22 region provides additional infor-
mation on NOA risk-associated variants (Figure 3). SNP
rs3129878 was the most significant at this region in stage
I (p ¼ 5.49 3 1015) and is located in intron 1 of HLA-
DRA (MIM 142860). Several other SNPs that were in
moderate LD (r2 z 0.4–0.6, green dots) or modest LD
(r2 z 0.2–0.4, light blue dots) with rs3129878 were also
highly significant (pz 1081010). Theywere in aweakly
defined haplotype block that contains two known genes,
HLA-DRA and BTNL2 (MIM 606000). One of these SNPs,
rs7192, is a nonsynonymous change in exon 4 of HLA-
DRA that results in an amino acid substitution from valine
to leucine. However, the p value of this SNP (p ¼ 9.66 3
108) was noticeably weaker than that of other flanking
SNPs; therefore, this nonsynonymous change is unlikely
to be the driver of the association observed at this region.
The other independent NOA-associated SNP (rs498422)
was not in LD with rs3129878 (r2 ¼ 0.01, blue dot). It is
located in a haplotype block that is different from that of
rs3129878 (Figure 3). These two haplotype blocks are sepa-
rated by a recombination hotspot. The SNP rs498422 is
within another gene, chromosomal open reading frame
10 (C6orf10). Multiple SNPs in the haplotype block were
also associated with NOA risk; however, the statistical
evidence for their association was weaker than that for
rs498422.
We evaluated whether the most significant findings
could tag the classical human leukocyte antigen (HLA)
alleles and then performed the imputation of the HLA
alleles through the approach suggested by De Bakker
et al.19 The most significant SNP, rs3129878, can be used
together with rs2516049 to tag for HLA-DRB*0405 (HLA-
DRB [MIM 142857]) in the CHB population. Using the
imputation approach, we found that the HLA-DRB*0405Figure 2. Manhattan Plot of Genome-
wide Association Analyses for Nonobstru-
sive Azoospermia
The x axis shows chromosomal positions.
The y axis shows –log10 p values from
allelic tests adjusted for age and first prin-
cipal component from a population strati-
fication analysis. The horizontal dashed
line indicates the preset threshold of p ¼
1 3 105. The horizontal solid line indi-
cates the preset threshold of genome-
wide significance: p ¼ 5 3 108.
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Table 1. GWAS, Case-Control Replication Study, and Metaanalysis Results for Significant SNPs
Independencea Alleleb Stage Case Ctrl ORc p Valuec HWEd Statuse Qf I2f ORg p Valueg ORh p Valueh
Chromosome 6, rs498422
Yes G/T GWAS 0.20 0.13 1.81 1.53 3 1011 0.36 G/I 0.006 80.12 1.42 2.43 3 1012 1.44 1.8 3 103
replication 1 0.17 0.13 1.37 1.46 3 104
replication 2 0.16 0.14 1.21 0.068
Chromosome 6, rs2076531
No G/A GWAS 0.11 0.06 2.03 1.49 3 109 0.67 I/G 0.04 67.84 1.61 6.60 3 1013 1.60 1.4 3 104
replication 1 0.10 0.07 1.42 9.75 3 104
replication 2 0.08 0.06 1.40 0.018
Chromosome 6, rs3129878
Yes C/A GWAS 0.40 0.29 1.63 1.03 3 1012 0.74 G/G 0.005 81.07 1.37 3.70 3 1016 1.36 9.0 3 104
replication 1 0.36 0.30 1.32 1.48 3 105
replication 2 0.32 0.28 1.17 0.051
Chromosome 6, rs7192
No T/G GWAS 0.32 0.26 1.42 1.02 3 106 0.58 G/I 0.19 39.42 1.28 1.10 3 109 1.29 2.9 3 106
replication 1 0.32 0.27 1.26 3.70 3 104
replication 2 0.29 0.26 1.17 0.050
Ctrl, control; OR, odds ratio; HWE, Hardy-Weinberg equilibrium.
a‘‘Independence’’ indicates whether the SNPs remained independently associated with NOA risk when adjusted for the other SNPs in the model.
bMinor allele/major allele.
cOR is estimated on the basis of the minor allele; OR and p values are estimated on the basis of logistic regression analysis, adjusted for age and the first two eigen
vectors, estimated on the basis of principal component analysis.
dHWE tests were based on Fisher’s exact tests in the combined control subjects.
eG, genotyped; I, imputed. The letter before the forward slash indicates the imputation status for cases, and the letter after the forward slash indicates the impu-
tation status for controls.
fThe p values of Q test and I2 values are based on tests for heterogeneity.
gThe combined analysis was based on logistic regression analysis, adjusted for age and stage information.
hThe combined analysis was based on metaanalysis, with the assumption of a random effect model.allele was significantly associated with increased NOA risk,
with a frequency of 0.087 in the cases and 0.05 in the
controls (p ¼ 7.9 3 107). Association of the HLA-DRB*
0405 allele with rheumatoid arthritis (MIM 180300) has
been reported in previous studies.20 The other independent
NOA-associated SNP (rs498422)didnot tag anyknownHLA
alleles in the CHB population. However, rs2076531, the
SNP in LDwith rs498422 (r2¼ 0.58 in CHB), is in complete
LD with rs2076528. The latter SNP, together with
rs1694112 and rs6937034, can tag for HLA-DQB*0402
(HLA-DQB [MIM604305]) in theCHBpopulation. Through
imputation analysis, we found that the HLA-DQB*0402
allele was also significantly associated with increased NOA
risk, with a frequency of 0.098 in the cases and 0.057 in
the controls (p ¼ 6.7 3 108). This HLA allele was found
to be associated with type 1 diabetes (MIM 222100).21
HLA-DRA is a member of HLA class II genes. It encodes
the alpha chain of HLA-DR and heterodimerizes with
beta chains (HLA-DRBs) anchoring in the cell membrane.
Like other HLA molecules (major histocompatibility
complex [MHC] class I and II), HLA-DRA plays an impor-
tant role in the immune system by presenting peptides
on the cell surface of antigen-presenting cells (APCs,The Amincluding B lymphocytes, dendritic cells, and macro-
phages) for recognition by T cells. BTNL2 encodes butyro-
philin-like 2, an immunoglobulin superfamily membrane
protein implicated in regulating Tcell activation. The func-
tion of C6orf10 is unknown. Several autoimmune diseases
have been reported to be associated with this region, such
as ulcerative colitis (MIM 266600),22 systemic lupus eryth-
ematosus (MIM 152700),23 vitiligo (MIM 606579),24
sarcoidosis (MIM 181000),25 multiple sclerosis (MIM
126200),26 and Parkinson disease(MIM 168600).27 Thus,
it is likely that variations in this region might mediate
the response to testicular microenvironmental antigens
and cause testicular azoospermia through autoimmune
inflammatory responses.
Spiess et al.28 performed global gene expression profiling
of testicular biopsies from azoospermia patients and iden-
tified inflammation-related genes involved in spermato-
genic failure. Our study of SNPs throughout the genome
further supports the involvement of the HLA region in
susceptibility to NOA and suggests that inflammation in
testicular tissues might cause the failure of interactions
between immune-germ and somatic testicular cells, dis-
rupting the process of spermatogenesis. Thus, controllingerican Journal of Human Genetics 90, 900–906, May 4, 2012 903
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Figure 3. Plots of the 6p22 Region
Top panel: the x axis shows chromosomal positions. The left y axis shows –log10 p values from an association test. Colors of the dots
indicate the LD relationship between the most significant associated SNP (rs3129878) and the remaining SNPs in the 200 kb region. The
right y axis shows the recombination rate between SNPs.
Bottom panel: Heatmap of SNPs at the region. Both the LD and recombination rates are estimated on the basis of the Hapmap phase II
CHB and JPT population.inflammation therapeutically may significantly improve
the disease outcomes.
Our results must be interpreted with caution. First, as
shown in Table 1, the magnitude of association differed
in the GWAS discovery stage and the replication 1 and 2
studies. The significant p values of the Q test and the rela-
tively high I2 statistics also indicated that certain levels of
heterogeneity existed in our study. In this situation,
a random effect model maybe more appropriate for esti-
mating the combined effect of the SNPs identified in our
study. However, assuming a random effect model would904 The American Journal of Human Genetics 90, 900–906, May 4, 2greatly reduce the statistical power in comparison to the
approach of using individual-level of data adjusted accord-
ing to study stage. In our case, the magnitude of associa-
tion significantly decreased (p ¼ 1.8 3 103 for rs498422
and p ¼ 9.0 3 104 for rs312987) when a random effect
model was assumed. Therefore, additional studies are war-
ranted if we are to infer a more stable estimate of the
magnitude of association of the SNPs identified here.
Second, an inflation factor of 1.08 was observed for the
GWAS stage. In this study, we have carefully applied a series
of quality control (QC) criteria to both individuals and012
SNPs, including removing samples with a low call rate,
unintended duplicated samples, and individuals who are
potentially related on the basis of identity-by-state esti-
mates. Population stratification was also evaluated, and
the first two eigen vectors were included as the covariate
in the analysis. A relatively high inflation factor of 1.08
remained after all of the QC criteria had been applied.
This may indicate some undetected population structure,
although adjusting additional eigen vectors did not result
in a lower inflation factor (data not shown). However,
when we calibrated the test statistics using the inflation
factor, it had a limited effect on our main findings. For
example, the magnitude of association for rs3129878
was slightly decreased from a p value of 1.03 3 1012 to
a p value of 7.03 3 1012 if we calibrated by dividing the
test statistics by the inflation factor of 1.08.
In summary, our GWAS and subsequent replication
analyses identified variants at the HLA region that are
associated with idiopathic NOA in the Han Chinese popu-
lation. These results highlight the possible involvement
of chronic immune activation pathways in the etiology
of NOA and point to a potential therapeutic target for
this disease.Supplemental Data
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